CUSATO, Jessica
 Distribuzione geografica
Continente #
NA - Nord America 10.253
EU - Europa 5.658
AS - Asia 1.769
AF - Africa 117
SA - Sud America 68
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 16
Totale 17.912
Nazione #
US - Stati Uniti d'America 10.167
DK - Danimarca 1.179
IT - Italia 1.154
CN - Cina 1.098
IE - Irlanda 703
SE - Svezia 548
FR - Francia 400
DE - Germania 326
UA - Ucraina 240
FI - Finlandia 228
AT - Austria 183
GB - Regno Unito 168
IN - India 143
VN - Vietnam 128
BE - Belgio 125
PL - Polonia 117
KR - Corea 111
NL - Olanda 94
JP - Giappone 92
CA - Canada 65
ZA - Sudafrica 55
ES - Italia 49
BR - Brasile 40
TW - Taiwan 30
AU - Australia 29
GR - Grecia 29
TH - Thailandia 29
HK - Hong Kong 27
CH - Svizzera 21
RU - Federazione Russa 21
TR - Turchia 21
RO - Romania 18
SG - Singapore 18
PK - Pakistan 16
MX - Messico 15
ID - Indonesia 14
EU - Europa 13
NG - Nigeria 13
UZ - Uzbekistan 13
PT - Portogallo 10
RS - Serbia 9
SN - Senegal 9
CL - Cile 8
EG - Egitto 7
IR - Iran 7
UG - Uganda 7
AR - Argentina 6
CO - Colombia 6
HR - Croazia 6
KE - Kenya 6
CZ - Repubblica Ceca 5
EC - Ecuador 5
NO - Norvegia 4
BG - Bulgaria 3
DZ - Algeria 3
KZ - Kazakistan 3
LV - Lettonia 3
MA - Marocco 3
MK - Macedonia 3
MU - Mauritius 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
HU - Ungheria 2
IQ - Iraq 2
LI - Liechtenstein 2
ME - Montenegro 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
A1 - Anonimo 1
AF - Afghanistan, Repubblica islamica di 1
BD - Bangladesh 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CU - Cuba 1
CY - Cipro 1
GE - Georgia 1
GM - Gambi 1
HN - Honduras 1
IL - Israele 1
JO - Giordania 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MZ - Mozambico 1
NA - Namibia 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
Totale 17.911
Città #
Ann Arbor 2.476
Chandler 1.340
Dublin 697
Beijing 631
Fairfield 561
Houston 443
Torino 427
Ashburn 335
Woodbridge 313
Wilmington 301
Dearborn 293
Nyköping 289
Villeurbanne 285
Seattle 207
Medford 200
Princeton 199
Vienna 176
Cambridge 170
Redwood City 168
Jacksonville 147
Brussels 109
Warsaw 101
Pisa 87
New York 84
Fremont 82
Turin 82
Dong Ket 63
Milan 60
Nanjing 52
Boston 50
Boardman 48
Guangzhou 44
Shanghai 40
San Diego 36
Toronto 34
Norwalk 32
Washington 32
Hangzhou 28
Hefei 27
Verona 24
Rome 23
Hebei 22
Taipei 22
London 20
Chengdu 19
Helsinki 18
Falls Church 17
Jinan 17
Los Angeles 17
Mountain View 16
Seoul 16
Chicago 15
Phoenix 15
Cape Town 14
Dallas 14
Florence 14
Kunming 14
Nanchang 14
Shenzhen 14
Tokyo 14
Alberton 12
Amsterdam 12
Mumbai 12
Paris 12
Pune 12
Rotterdam 12
Kharkiv 11
Xian 11
Bengaluru 10
Lappeenranta 10
Nürnberg 10
Piemonte 10
Silver Spring 10
Chongqing 9
Esslingen am Neckar 9
Hyderabad 9
Minneapolis 9
Ottawa 9
Philadelphia 9
Upper Marlboro 9
Abuja 8
Belgrade 8
Chennai 8
Copenhagen 8
Des Moines 8
Edinburgh 8
Genoa 8
Montreal 8
San Mateo 8
Bologna 7
Buffalo 7
Central District 7
Gurgaon 7
Islamabad 7
Shenyang 7
Sydney 7
São Paulo 7
Tianjin 7
Wuhan 7
Zurich 7
Totale 11.464
Nome #
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 405
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 365
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 330
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 302
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 295
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 291
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 273
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 267
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 258
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 245
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 237
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 233
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 232
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 228
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 224
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 211
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 209
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 201
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 196
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 191
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 185
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 185
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 181
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment 180
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 175
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 171
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 168
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 168
Role of pharmacogenetics on deferasirox AUC and efficacy 166
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 165
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 164
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 162
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 159
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia 159
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 158
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 153
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 152
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 152
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 152
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 151
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 150
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 147
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 145
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 144
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 142
Discordant results for IL28B genotyping (rs12979860 vs. rs8099917) and the prediction of rapid viral response in chronic hepatitis C 140
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 137
Pharmacogenetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 135
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 135
Influenza della somministrazione del metadone sulle concentrazioni plasmatiche di daclatasvir in una coorte di pazienti con epatite cronica da HCV e tossicodipendenza attiva. 134
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 133
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 131
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 129
Pharmacogenetics of ribavirin-induced anemia in HCV patients 128
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 127
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 126
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs 125
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 124
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 124
Ruolo della riduzione precoce di HBsAg per individuare i pazienti con infezione precoce da HBV, HBeAg-negativi e genotipo E ad alta probabilità di risposta sostenuta con 48 settimane di trattamento con PEG-INF ALFA-2A 120
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children 120
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 120
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 117
Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study 112
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 107
Cannabinoids concentration variability in cannabis olive oil galenic preparations 107
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 98
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma 96
Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring? 95
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 94
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 94
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 93
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 92
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 91
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 88
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 88
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients 88
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients 87
Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients 86
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness. 84
Deferasirox AUC efficacy cutoff and role of pharmacogenetics 84
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 84
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 83
The "scar" of a pandemic: cumulative incidence of COVID-19 during the first trimester of pregnancy 83
Efavirenz pharmacogenetics in a cohort of Italian patients 81
Pharmacokinetics of simeprevir and risk of skin reactions in patients with co-infection HIV/HCV with or without a protease inhibitor containing HAART 81
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 81
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 80
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 79
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 77
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness 77
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 77
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 76
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 75
Clinical relevance of deferasirox trough levels in β-thalassemia patients 73
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 73
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 71
Totale 14.909
Categoria #
all - tutte 45.517
article - articoli 0
book - libri 0
conference - conferenze 8.991
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.508


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019640 0 0 0 0 0 0 0 0 58 167 270 145
2019/20203.404 92 87 91 266 362 662 285 185 222 371 352 429
2020/20212.213 323 113 76 128 144 165 108 78 188 165 287 438
2021/20224.029 326 309 340 378 271 366 363 299 209 153 545 470
2022/20233.891 353 335 137 329 342 890 261 333 415 102 270 124
2023/20241.176 224 272 115 75 111 209 60 81 29 0 0 0
Totale 18.889